A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)

NCT01600092 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1020

Enrollment

INDUSTRY

Sponsor class

Conditions

Rotavirus Gastroenteritis

Interventions

BIOLOGICAL: RotaTeq™ experimental formulation
BIOLOGICAL: RotaTeq™ existing formulation

Sponsor

Merck Sharp & Dohme LLC